par Duszynska, Wieslawa;Taccone, Fabio ;Hurkacz, Magdalena;Kowalska-Krochmal, Beata;Wiela-Hojeńska, Anna;Kübler, Andrzej
Référence Critical care, 17, 4, page (R165)
Publication Publié, 2013-07
Référence Critical care, 17, 4, page (R165)
Publication Publié, 2013-07
Article révisé par les pairs
Résumé : | Use of higher than standard doses of amikacin (AMK) has been proposed during sepsis, especially to treat less susceptible bacterial strains. However, few data are available on drug concentrations during prolonged therapy and on potential adverse events related to this strategy. |